Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trial

Michele Reni, Elisa Bonetto, Stefano Cordio, Paolo Passoni, Carlo Milandri, Stefano Cereda, Anna Spreafico, Laura Galli, Roberto Bordonaro, Carlo Staudacher, Valerio Di Carlo, Colin D. Johnson

Research output: Contribution to journalArticlepeer-review


Background: A phase III trial suggested that a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma. The analysis of treatment impact on quality of life (QOL) is reported. Method: Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and PAN-26 questionnaires at baseline and every second month of treatment until disease progression. Results: The largest differences between arms favored PEFG. Expressed as improvement ≥10 points from baseline (PEFG/gemcitabine), these were: emotional function (43/18%), fatigue (41/17%), QOL (55/29%), pain (64/41%), and flatulence (50/26%). Only change in sexual function favored gemcitabine (19/42%). Physical function, fatigue, appetite, and satisfaction with healthcare improved in 40-46% of partial responders compared with 0-12% of patients with stable disease. Conclusion: Clinically relevant improvement in QOL from baseline was observed more often after PEFG than after gemcitabine, suggesting that the PEFG regimen did not impair QOL, Partial response was associated with improved QOL suggesting that effective treatment of pancreatic adenocarcinoma may have an important role in these patients.

Original languageEnglish
Pages (from-to)454-463
Number of pages10
Issue number5
Publication statusPublished - Oct 2006


  • Gemcitabine
  • Pancreatic cancer
  • PEFG regimen
  • Phase III trial
  • Quality of life

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology


Dive into the research topics of 'Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trial'. Together they form a unique fingerprint.

Cite this